Agomelatine: a new treatment for depression

Future Prescriber Pub Date : 2009-04-28 DOI:10.1002/fps.48
Professor Bill Deakin
{"title":"Agomelatine: a new treatment for depression","authors":"Professor Bill Deakin","doi":"10.1002/fps.48","DOIUrl":null,"url":null,"abstract":"<p>It is estimated that depression carries the greatest burden of disability in established economies. A range of treatments are available, and selective serotonin reuptake inhibitors (SSRIs) are currently the most commonly prescribed class of antidepressant. In this article, the author discusses agomelatine, a novel antidepressant recently licensed by the European Medicines Agency (EMEA), the evidence for its use, and its potential place in therapy. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 2","pages":"14-19"},"PeriodicalIF":0.0000,"publicationDate":"2009-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.48","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

It is estimated that depression carries the greatest burden of disability in established economies. A range of treatments are available, and selective serotonin reuptake inhibitors (SSRIs) are currently the most commonly prescribed class of antidepressant. In this article, the author discusses agomelatine, a novel antidepressant recently licensed by the European Medicines Agency (EMEA), the evidence for its use, and its potential place in therapy. Copyright © 2009 John Wiley & Sons, Ltd.

阿戈美拉汀:一种治疗抑郁症的新方法
据估计,在成熟经济体中,抑郁症是造成残疾的最大负担。治疗方法有很多,选择性血清素再摄取抑制剂(SSRIs)是目前最常用的抗抑郁药。在这篇文章中,作者讨论了阿戈美拉汀,一种最近获得欧洲药品管理局(EMEA)许可的新型抗抑郁药,它的使用证据,以及它在治疗中的潜在地位。版权所有©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信